D. E. Shaw & Co., Inc. Kura Oncology, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KURA
# of Institutions
174Shares Held
80.4MCall Options Held
914KPut Options Held
120K-
Suvretta Capital Management, LLC New York, NY7.07MShares$142 Million6.46% of portfolio
-
Black Rock Inc. New York, NY6.9MShares$138 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.81MShares$116 Million3.53% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.41MShares$109 Million2.38% of portfolio
-
Bvf Inc San Francisco, CA4.79MShares$96 Million3.06% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $1.34B
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...